NO20032895L - Dihydronaftalenderivat-forbindelser og legemidler innholdende disse forbindelsene som den aktive bestanddel - Google Patents

Dihydronaftalenderivat-forbindelser og legemidler innholdende disse forbindelsene som den aktive bestanddel

Info

Publication number
NO20032895L
NO20032895L NO20032895A NO20032895A NO20032895L NO 20032895 L NO20032895 L NO 20032895L NO 20032895 A NO20032895 A NO 20032895A NO 20032895 A NO20032895 A NO 20032895A NO 20032895 L NO20032895 L NO 20032895L
Authority
NO
Norway
Prior art keywords
agent
compounds
compound
formula
active ingredient
Prior art date
Application number
NO20032895A
Other languages
English (en)
Other versions
NO327132B1 (no
NO20032895D0 (no
Inventor
Hisao Tajima
Yoshisuke Nakayama
Daikichi Fukushima
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of NO20032895D0 publication Critical patent/NO20032895D0/no
Publication of NO20032895L publication Critical patent/NO20032895L/no
Publication of NO327132B1 publication Critical patent/NO327132B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20032895A 2000-12-25 2003-06-23 Dihydronaftalenderivat-forbindelser og legemidler innholdende disse forbindelsene som den aktive bestanddel NO327132B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000392723 2000-12-25
PCT/JP2001/011255 WO2002051820A1 (en) 2000-12-25 2001-12-21 Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient

Publications (3)

Publication Number Publication Date
NO20032895D0 NO20032895D0 (no) 2003-06-23
NO20032895L true NO20032895L (no) 2003-08-25
NO327132B1 NO327132B1 (no) 2009-04-27

Family

ID=18858667

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032895A NO327132B1 (no) 2000-12-25 2003-06-23 Dihydronaftalenderivat-forbindelser og legemidler innholdende disse forbindelsene som den aktive bestanddel

Country Status (23)

Country Link
US (2) US7220864B2 (no)
EP (2) EP1354879B1 (no)
JP (1) JP3491635B2 (no)
KR (2) KR100718906B1 (no)
CN (1) CN100357280C (no)
AT (1) ATE370130T1 (no)
BR (1) BR0116526A (no)
CA (1) CA2432211C (no)
CZ (1) CZ20031772A3 (no)
DE (1) DE60130031T2 (no)
DK (1) DK1354879T3 (no)
ES (1) ES2291378T3 (no)
HU (1) HUP0303636A3 (no)
IL (2) IL156505A0 (no)
MX (1) MXPA03005763A (no)
NO (1) NO327132B1 (no)
NZ (1) NZ526687A (no)
PL (1) PL207798B1 (no)
PT (1) PT1354879E (no)
RU (1) RU2268262C2 (no)
TW (1) TWI235748B (no)
WO (1) WO2002051820A1 (no)
ZA (1) ZA200304913B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
WO2004011446A1 (en) * 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308354A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de) * 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
JPWO2005103017A1 (ja) * 2004-04-20 2008-03-13 小野薬品工業株式会社 難溶性薬物の比表面積増大方法
CA2626443A1 (en) * 2005-11-07 2007-05-18 Irm Llc Oxazole and thiazole ppar modulators
WO2010047674A1 (en) 2008-10-20 2010-04-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Low molecular weight thyroid stimulating hormone receptor (tshr) agonists
JP5965387B2 (ja) 2010-04-08 2016-08-03 アメリカ合衆国 Ｔｓｈ受容体用のインバースアゴニストおよびニュートラルアンタゴニスト
US20130158063A1 (en) * 2010-08-24 2013-06-20 Georgetown University Compounds, Compositions and Methods Related to PPAR Antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
WO1999011255A1 (en) * 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Peroxisome proliferator-activated receptor controllers

Also Published As

Publication number Publication date
EP1354879A1 (en) 2003-10-22
CN1489582A (zh) 2004-04-14
HUP0303636A2 (hu) 2004-03-01
EP1354879A4 (en) 2004-09-22
DE60130031D1 (de) 2007-09-27
EP1726586A1 (en) 2006-11-29
EP1354879B1 (en) 2007-08-15
CZ20031772A3 (cs) 2003-11-12
ZA200304913B (en) 2004-01-22
JPWO2002051820A1 (ja) 2004-04-22
DK1354879T3 (da) 2007-12-17
JP3491635B2 (ja) 2004-01-26
CN100357280C (zh) 2007-12-26
MXPA03005763A (es) 2004-05-03
ATE370130T1 (de) 2007-09-15
KR20030064871A (ko) 2003-08-02
KR20060083436A (ko) 2006-07-20
US7220864B2 (en) 2007-05-22
CA2432211A1 (en) 2002-07-04
RU2268262C2 (ru) 2006-01-20
PT1354879E (pt) 2007-10-29
US20040138213A1 (en) 2004-07-15
KR100718906B1 (ko) 2007-05-18
NO327132B1 (no) 2009-04-27
PL363583A1 (en) 2004-11-29
ES2291378T3 (es) 2008-03-01
PL207798B1 (pl) 2011-02-28
HUP0303636A3 (en) 2006-02-28
WO2002051820A1 (en) 2002-07-04
IL156505A (en) 2009-09-22
NO20032895D0 (no) 2003-06-23
IL156505A0 (en) 2004-01-04
DE60130031T2 (de) 2008-05-15
TWI235748B (en) 2005-07-11
US20060287304A1 (en) 2006-12-21
BR0116526A (pt) 2004-07-06
NZ526687A (en) 2004-08-27
KR100635315B1 (ko) 2006-10-18
CA2432211C (en) 2010-07-13

Similar Documents

Publication Publication Date Title
EP1067109A4 (en) CARBOXYLIC ACID DERIVATIVES AND MEDICAMENTS CONTAINING THESE DERIVATIVES AS ACTIVE INGREDIENT
NO20032895D0 (no) Dihydronaftalenderivat-forbindelser og legemidler innholdende disse forbindelsene som den aktive bestanddel
WO2001096311A3 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
EP1122255A4 (en) CARBONIC ACID DERIVATIVES AND MEDICINES THAT CONTAIN THEM AS ACTIVE INGREDIENTS
MY142551A (en) Substituted diaryl heterocycles, process for their preparation and their use as medicaments
DE60009929D1 (de) Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
ATE310733T1 (de) Thyroid-rezeptorliganden
BR0016064A (pt) Compostos heterocìclicos e seus sais e uso medicinal dos mesmos
EP1219595A4 (en) O anisamide DERIVATIVES
EP1108713A4 (en) CARBOXYLENE DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE COMPONENT
RU2006102129A (ru) Производные пиррол-2, 5-дитиона в качестве модуляторов печеночных х-рецепторов
NO20025659D0 (no) Heterocykliske forbindelser
DK0682947T3 (da) Medikament til terapeutisk og profylaktisk behandling af sygdomme forårsaget af glatmuskelcelle-hyperplasi
BRPI0408325A (pt) compostos derivados de imino éter e medicamentos contendo os compostos como o ingrediente ativo
NO305082B1 (no) 2-(4-(4-azolbutyl)-1-piperazinyl)-5-hydroksy-pyrimidinderivater, deres fremstilling og anvendelse som legemidler
WO2003042194A1 (en) Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
CA2365085A1 (en) Therapeutic agents for diabetes
UA89807C2 (ru) Производные 3-фенилпропионовой кислоты для лечения диабета
ATE278701T1 (de) Malto-oligosaccharide und deren verwendung
Lavery 5 Questions—and Answers—About Off-Loading
NO20042881L (no) Substituerte cykloheksan-derivater
RU2003120073A (ru) Увеличивающие содержание авса-1 соединения
FR2822069B1 (fr) Composition pharmaceutique comprenant un compose stimulant la secretion d'insuline et un derive de thiazolidinedione et son utilisation pour la preparation de medicamments destines a traiter le diabete
Shaban et al. Mo-P5: 328 Comparison of effective factors on sleeping from aspect of nurse and hospitalized patient in coronary care unit of hospitals of Tehran University of medical sciences
BR0210128A (pt) Combinação farmacêutica, método de tratamento ou de prevenção de diabetes, método de tratamento da sìndrome de resistência à insulina, kit de partes, produto combinado, e, método de produção de um produto combinado

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees